Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Paula Cannon, PhD

    TitleProfessor of Molecular Microbiology & Immunology
    SchoolKeck School of Medicine of USC
    DepartmentMolecular Microbiology and Immunology
    AddressHMR 413A 2011 Zonal Avenue
    Health Sciences Campus
    Los Angeles California 90089
    Phone+1 323 442 1510
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Cannon Lab Website

      Paula Cannon, PhD, is an Associate Professor of Microbiology at the Keck School of Medicine of USC, where she leads a research team that studies viruses, stem cells and gene therapy. She obtained her PhD from the University of Liverpool in the United Kingdom, and received postdoctoral training as an HIV scientist at both Oxford and Harvard universities. Although HIV remains the main focus of her work, she also studies highly pathogenic hemorrhagic fever viruses, including Ebola and Lassa fever viruses. Cannon has a long-standing interest in the development of gene therapy as a clinical approach to treating HIV infection, and her recent work in this area is aimed at disrupting the viral co-receptor, CCR5, using zinc finger nucleases (ZFNs). This approach is being evaluated in human hematopoietic stem cells to address whether such a therapy could result in a "functional cure" for AIDS patients. Cannon’s research is funded by both the National Institutes of Health and the California Institute for Regenerative Medicine.


      Collapse ORNG Applications 
      Collapse Websites
      Collapse Featured Videos
      Collapse In The News
      Collapse Twitter

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle PA, Wollmann G, von Laer D, Drexler I, Rathbun J, Cannon P, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang PA, Lang KS. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun. 2017 Mar 01; 8:14447. PMID: 28248314.
        View in: PubMed
      2. Corrigan-Curay J, O'Reilly M, Kohn DB, Cannon P, Bao G, Bushman FD, Carroll D, Cathomen T, Joung JK, Roth D, Sadelain M, Scharenberg AM, von Kalle C, Zhang F, Jambou R, Rosenthal E, Hassani M, Singh A, Porteus MH. Genome Editing Technologies: Defining a Path to Clinic: Genomic Editing: Establishing Preclinical Toxicology Standards, Bethesda, Maryland 10 June 2014. Mol Ther. 2015 May; 23(5):796-806. PMID: 28142000.
        View in: PubMed
      3. Wang CX, Cannon P. Clinical Applications of Genome Editing to HIV Cure. AIDS Patient Care STDS. 2016 Nov 17. PMID: 27854119.
        View in: PubMed
      4. DiGiusto DL, Cannon P, Holmes MC, Li L, Rao A, Wang J, Lee G, Gregory PD, Kim KA, Hayward SB, Meyer K, Exline C, Lopez E, Henley J, Gonzalez N, Bedell V, Stan R, Zaia JA. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev. 2016; 3:16067. PMID: 27900346.
        View in: PubMed
      5. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016 Aug; 22(8):839-50. PMID: 27400264.
        View in: PubMed
      6. Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon P, Kast WM. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 Jul; 30(7):291-306. PMID: 27410493.
        View in: PubMed
      7. Wang CX, Cannon P. The clinical applications of genome editing in HIV. Blood. 2016 May 26; 127(21):2546-52. PMID: 27053530.
        View in: PubMed
      8. Lederman MM, Cannon P, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC. A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathog Immun. 2016; 1(1):154-164. PMID: 27668293.
        View in: PubMed
      9. Wang J, Exline CM, DeClercq JJ, Llewellyn GN, Hayward SB, Li PW, Shivak DA, Surosky RT, Gregory PD, Holmes MC, Cannon P. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol. 2015 Dec; 33(12):1256-1263. PMID: 26551060.
        View in: PubMed
      10. Exline CM, Yang SJ, Haworth KG, Rengarajan S, Lopez LA, Droniou ME, Seclen E, Cannon P. Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology. 2015; 12(1):67. PMID: 26248668.
        View in: PubMed
      11. Rathbun JY, Droniou ME, Damoiseaux R, Haworth KG, Henley JE, Exline CM, Choe H, Cannon P. Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening. J Virol. 2015 Aug 15; 89(16):8428-43. PMID: 26041296.
        View in: PubMed
      12. Corrigan-Curay J, O'Reilly M, Kohn DB, Cannon P, Bao G, Bushman FD, Carroll D, Cathomen T, Joung JK, Roth D, Sadelain M, Scharenberg AM, von Kalle C, Zhang F, Jambou R, Rosenthal E, Hassani M, Singh A, Porteus MH. Genome editing technologies: defining a path to clinic. Mol Ther. 2015 May; 23(5):796-806. PMID: 25943494.
        View in: PubMed
      13. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon P, Seaman MS, Farzan M. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015 Mar 5; 519(7541):87-91. PMID: 25707797.
        View in: PubMed
      14. Cannon P, Kohn DB, Kiem HP. HIV eradication-from Berlin to Boston. Nat Biotechnol. 2014 Apr 8; 32(4):315-6. PMID: 24714473.
        View in: PubMed
      15. Hofer U, Henley JE, Exline CM, Mulhern O, Lopez E, Cannon P. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. J Infect Dis. 2013 Nov; 208 Suppl 2:S160-4. PMID: 24151324.
        View in: PubMed
      16. Li L, Krymskaya L, Wang J, Henley J, Rao A, Cao LF, Tran CA, Torres-Coronado M, Gardner A, Gonzalez N, Kim K, Liu PQ, Hofer U, Lopez E, Gregory PD, Liu Q, Holmes MC, Cannon P, Zaia JA, DiGiusto DL. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther. 2013 Jun; 21(6):1259-69. PMID: 23587921.
        View in: PubMed
      17. Droniou-Bonzom ME, Cannon P. A systems biology starter kit for arenaviruses. Viruses. 2012 Dec; 4(12):3625-46. PMID: 23342371.
        View in: PubMed
      18. Lopez LA, Yang SJ, Exline CM, Rengarajan S, Haworth KG, Cannon P. Anti-Tetherin Activities of HIV-1 Vpu and Ebola Virus Glycoprotein Do Not Involve Removal of Tetherin from Lipid Rafts. J Virol. 2012 May; 86(10):5467-80. PMID: 22398279.
        View in: PubMed
      19. Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Exline CM, Rathbun JY, Cannon P. Substitutions in the Glycoprotein (GP) of the Candid#1 Vaccine Strain of Junin Virus Increase Dependence on Human Transferrin Receptor 1 for Entry and Destabilize the Metastable Conformation of GP. J Virol. 2011 Dec; 85(24):13457-62. PMID: 21976641.
        View in: PubMed
      20. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon P. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology. 2011; 8:78. PMID: 21955466.
        View in: PubMed
      21. Cannon P, June C. Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS. 2011 Jan; 6(1):74-9. PMID: 21242897.
        View in: PubMed
      22. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon P. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010 Aug; 28(8):839-47. PMID: 20601939.
        View in: PubMed
      23. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon P. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology. 2010; 7:51. PMID: 20529266.
        View in: PubMed
      24. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon P. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol. 2010 Jul; 84(14):7243-55. PMID: 20444895.
        View in: PubMed
      25. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon P. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology. 2010; 7:13. PMID: 20167081.
        View in: PubMed
      26. Christodoulopoulos I, Droniou-Bonzom ME, Oldenburg JE, Cannon P. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology. 2010; 7:4. PMID: 20102634.
        View in: PubMed
      27. Lucas TM, Lyddon TD, Cannon P, Johnson MC. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu. J Virol. 2010 Mar; 84(6):2666-74. PMID: 20042505.
        View in: PubMed
      28. Sumiyoshi T, Holt NG, Hollis RP, Ge S, Cannon P, Crooks GM, Kohn DB. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther. 2009 Dec; 20(12):1607-26. PMID: 19689196.
        View in: PubMed
      29. Martin VK, Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Cannon P. Investigation of clade B New World arenavirus tropism by using chimeric GP1 proteins. J Virol. 2010 Jan; 84(2):1176-82. PMID: 19889757.
        View in: PubMed
      30. Flanagan ML, Oldenburg J, Reignier T, Holt N, Hamilton GA, Martin VK, Cannon P. New world clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. J Virol. 2008 Jan; 82(2):938-48. PMID: 18003730.
        View in: PubMed
      31. Reignier T, Oldenburg J, Flanagan ML, Hamilton GA, Martin VK, Cannon P. Receptor use by the Whitewater Arroyo virus glycoprotein. Virology. 2008 Feb 20; 371(2):439-46. PMID: 17997467.
        View in: PubMed
      32. Weber EL, Cannon P. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther. 2007 Sep; 18(9):849-60. PMID: 17767401.
        View in: PubMed
      33. Oldenburg J, Reignier T, Flanagan ML, Hamilton GA, Cannon P. Differences in tropism and pH dependence for glycoproteins from the Clade B1 arenaviruses: implications for receptor usage and pathogenicity. Virology. 2007 Jul 20; 364(1):132-9. PMID: 17397892.
        View in: PubMed
      34. Reignier T, Oldenburg J, Noble B, Lamb E, Romanowski V, Buchmeier MJ, Cannon P. Receptor use by pathogenic arenaviruses. Virology. 2006 Sep 15; 353(1):111-20. PMID: 16797051.
        View in: PubMed
      35. Noble B, Abada P, Nunez-Iglesias J, Cannon P. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol. 2006 Mar; 80(6):2924-32. PMID: 16501101.
        View in: PubMed
      36. Abada P, Noble B, Cannon P. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol. 2005 Mar; 79(6):3627-38. PMID: 15731257.
        View in: PubMed
      37. Aguilar HC, Anderson WF, Cannon P. Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide. J Virol. 2003 Jan; 77(2):1281-91. PMID: 12502845.
        View in: PubMed
      38. Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, Barcova M, Cannon P, Mazurek C, Woodley DT. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet. 2002 Dec; 32(4):670-5. PMID: 12426566.
        View in: PubMed
      39. Lin AH, Cannon P. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res. 2002 Feb 26; 83(1-2):43-56. PMID: 11864740.
        View in: PubMed